Genzyme sells pharmaceuticals segment

Monday, March 7, 2011 10:49 AM

Cambridge, Mass.-based Genzyme has completed the sale of its pharmaceutical intermediates business to Germany's International Chemical Investors Group for an undisclosed amount, according to BIOSmartBrief.

Genzyme said selling the unit will allow it to focus on its core businesses.  ICIG acquired all of Genzyme's pharmaceutical intermediates business excluding drug delivery technologies.

Approximately 120 Genzyme workers will remain employed by the new business, which will be called Corden Pharma Switzerland.

Corden Pharma has offices in Switzerland and Boston and will supply Genzyme with materials needed to produce eliglustat tartrate, an investigational treatment for Gaucher disease type 1 currently in phase III clinical trials. Corden will also supply materials needed for other treatments.

Genzyme announced last month it would be acquired by French drugmaker Sanofi-aventis.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs